720 related articles for article (PubMed ID: 32109485)
1. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Novotny-Diermayr V; Sausgruber N; Loh YK; Pasha MK; Jayaraman R; Hentze H; Yong WP; Goh BC; Toh HC; Ethirajulu K; Zhu J; Wood JM
Mol Cancer Ther; 2011 Jul; 10(7):1207-17. PubMed ID: 21586629
[TBL] [Abstract][Full Text] [Related]
5. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
6. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
Rahimian A; Barati G; Mehrandish R; Mellati AA
Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
[TBL] [Abstract][Full Text] [Related]
7. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
9. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
10. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Yang L; Chang Y; Cao P
Exp Cell Res; 2018 Oct; 371(1):231-237. PubMed ID: 30107147
[TBL] [Abstract][Full Text] [Related]
11. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Zhang T; Chen Y; Li J; Yang F; Wu H; Dai F; Hu M; Lu X; Peng Y; Liu M; Zhao Y; Yi Z
Neoplasia; 2014 Aug; 16(8):665-77. PubMed ID: 25220594
[TBL] [Abstract][Full Text] [Related]
12. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.
Wang Y; Fu D; Chen Y; Su J; Wang Y; Li X; Zhai W; Niu Y; Yue D; Geng H
Cell Death Dis; 2018 May; 9(5):501. PubMed ID: 29717134
[TBL] [Abstract][Full Text] [Related]
13. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
17. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
18. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
19. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Shah P; Gau Y; Sabnis G
Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]